Asymmetric dimethylarginine: Relationship with circulating biomarkers of inflammation and cardiovascular disease risk in uncomplicated obese women

European Journal of Inflammation

Volumn 9, Issue 3, 2011, Pages 249-255

  Dozio, Elena ^a   Malavazos, A E ^b   Dogliotti, G ^a   Goggi, S ^b   Galliera, E ^a   Solimene, U ^a   Magni, P ^a   Costa, E ^b   Morricone, L ^b   Corsi, M M ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS POLICLINICO SAN DONATO   (Italy)

Author keywords

Asymmetric dimethylarginine; Cardiovascular risk; Inflammation; Obesity

Indexed keywords

BIOLOGICAL MARKER; HOMOCYSTEINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; N(G),N(G) DIMETHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ABDOMINAL SUBCUTANEOUS FAT; ADULT; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; INFLAMMATION; OBESITY; PATHOGENESIS; PREDICTION; REGRESSION ANALYSIS; RISK FACTOR;

EID: 84858630698     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1100900305     Document Type: Article

References (31)

1. Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010; 17:4511-20.
2. Schade D, Kotthaus J, Clement B. Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease 2010; Pharmacol Ther 126: 279-300.
3. Tracy RP. Is visceral adiposity the "enemy within"? Arterioscler Thromb Vasc Biol 2001; 21:881-3.
4. Yudkin JS. Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003; 27(S):25-8.
5. Zoccali C, Mallamaci F, Tripepi G. Adipose tissue as a source of inflammatory cytokines in health and disease: focus on end-stage renal disease. Kidney Int 2003; (S)65-8.
6. Trayhurn P. Of genes and genomes - and dark matter. Br J Nutr 2004; 91:1-2. (Pubitemid 38100553)
7. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444:875-80. (Pubitemid 46028447)
8. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82:4196-200. (Pubitemid 27525539)
9. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259:87-91. (Pubitemid 23036092)
10. Mulvihill NT, Foley JB, Crean P, Walsh M. Prediction of cardiovascular risk using soluble cell adhesion molecules. Eur Heart J 2002; 23:1569-74. (Pubitemid 35221560)
11. Lemieux I, Pascot A, Prud'homme D, Aimeras N, Bogaty P, Nadeau A, Bergeron J, Despres JP. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol 2001; 21:961-7. (Pubitemid 34168653)
12. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, Molinari AM, Giugliano D. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804-9. (Pubitemid 34174919)
13. Forouhi NG, Sattar N, McKeigue PM. Relation of C-reactive protein to body fat distribution and features of the metabolic syndrome in Europeans and South Asians. Int J Obes Relat Metab Disord 2001; 25:1327-31. (Pubitemid 32835450)
14. Anderssohn M, Schwedhelm E, Luneburg N, Vasan RS, Boger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010; 7:105-18.
15. Spoto B, Parlongo RM, Parlongo G, Sgro E, Zoccali C. The enzymatic machinery for ADMA synthesis and degradation is fully expressed in human adipocytes. J Nephrol 2007; 20:554-9.
16. Cetinalp-Demircan P, Can A, Bekpinar S, Unlucerci Y, Orhan Y. Unchanged asymmetric dimethylarginine levels in non-diabetic, premenopausal obese women who have common risk factors for cardiovascular disease. Endocrine 2007; 31:100-4. (Pubitemid 350195141)
17. Gruber HJ, Mayer C, Meinitzer A, et al. Asymmetric dimethylarginine (ADMA) is tightly correlated with growth in juveniles without correlations to obesity related disorders. Exp Clin Endocrinol Diabetes 2008; 116:520-4.
18. Malavazos AE, Corsi MM, Ermetici F, Coman C, Sardanelli F, Rossi A, Morricone L, Ambrosi B. Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis 2007; 17:294-302. (Pubitemid 46551684)
19. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92:347-55. (Pubitemid 40277057)
20. Jung SH, Park HS, Kim KS, et al. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. J Nutr Biochem 2008; 19:371-5. (Pubitemid 351695511)
21. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 2004; 53:1574-9. (Pubitemid 39556372)
22. Konukoglu D, Uzun H, Firtina S, Cigdem Arica P, Kocael A, Taskin M. Plasma adhesion and inflammation markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before and after laparoscopic gastric banding in morbidly obese patients. Obes Surg 2007; 17:672-8. (Pubitemid 46950641)
23. Topal G, Donmez A, Dogan BS, Kucur M, Cengiz DT, Berkoz FB, Erdogan N. Asymmetric dimethylarginine (ADMA) levels are increased in patients with fibromyalgia: Correlation with tumor necrosis factor-alpha (TNF-alpha) and 8-isoprostaglandin F(2alpha) (8-iso-PGF(2alpha)). Clin Biochem 2011; 44:364-7.
24. Mookerjee RP, Dalton RN, Davies NA, Hodges SJ, Turner C, Williams R, Jalan R. Inflammation is an important determinant of levels of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) in acute liver failure. Liver Transpl 2007; 13:400-5. (Pubitemid 46444469)
25. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-5. (Pubitemid 29289071)
26. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 2001; 15:43-58. (Pubitemid 32061655)
27. Hurst SM, Wilkinson TS, McLoughlin RM, et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14:705-14. (Pubitemid 32592418)
28. De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minenna A, Di Bari L, Pannacciulli N, Giorgino R. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997; 21:527-35. (Pubitemid 27273497)
29. Zhou J, Austin RC. Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms. Biofactors 2009; 35:120-9.
30. Karatela RA, Sainani GS. Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J 2009; 61:156-9.
31. Kumagai H, Sakurai M, Takita T, Maruyama Y, Uno S, Ikegaya N, Kato A, Hishida A. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am J Kidney Dis 2006; 48:797-805. (Pubitemid 44740047)